Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Most often read

Vol. 31. Issue. 1

29628

Evolving portal hypertension through Baveno VII recommendations

Manuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos

Ann Hepatol. 2024;29:101180

29628

Full text access

Share

28830

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis

Shudi Li, Fei Duan, Suling Li, Baoping Lu

Ann Hepatol. 2024;29:101174

28830

Full text access

Share

27323

Alcohol-related liver disease: A global perspective

Graciela Elia Castro Narro, Luis Antonio Díaz, Eric Kauffman Ortega, María Fernanda Bautista Garín, Eira Cerda Reyes, Pindaro Sebastian Martinez Delfin, Juan Pablo Arab, Ramón Bataller

Ann Hepatol. 2024;29:101499

27323

Full text access

Share

14928

From NAFLD to MASLD: When metabolic comorbidity matters

Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei

Ann Hepatol. 2024;29:101281

14928

Full text access

Share

12023

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT

Jeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon

Ann Hepatol. 2024;29:101280

12023

Full text access

Share

10927

Why a pinch of zinc in liver disease matters

Kurt Grüngreiff, Dirk Reinhold, Wolfgang Maret

Ann Hepatol. 2024;29:101152

10927

Full text access

Share

10855

Pathophysiology of ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problem

Gabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, ... Héctor Solar

Ann Hepatol. 2024;29:101498

10855

Full text access

Share

10364

Alcohol-associated liver disease: Epidemiology and management

Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller

Ann Hepatol. 2024;29:101162

10364

Full text access

Share

9607

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease

Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam

Ann Hepatol. 2024;29:101512

9607

Full text access

Share

8800

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group

Ann Hepatol. 2024;29:101133

8800

Full text access

Share

8593

Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents

Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra

Ann Hepatol. 2024;29:101182

8593

Full text access

Share

8403

The burden of liver disease in Latin America

Luis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese

Ann Hepatol. 2024;29:101175

8403

Full text access

Share

7181

The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease

Mingkai Li, Ying Lin, Hongsheng Yu, Weichun Lin, Jianning Chen, Yidong Yang, Bin Wu

Ann Hepatol. 2024;29:101516

7181

Full text access

Share

6917

Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Bryan A. Priego-Parra, Arturo Triana-Romero, Génesis P. Martínez-Pérez, Sara A. Reyes-Diaz, Héctor R. Ordaz-Alvarez, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, ... José M. Remes-Troche

Ann Hepatol. 2024;29 Supl 2:101391

6917

Full text access

Share

5977

Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018

Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang

Ann Hepatol. 2024;29:101154

5977

Full text access

Share

5274

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease

Francisco Barrera, Javier Uribe, Nixa Olvares, Paula Huerta, Daniel Cabrera, Manuel Romero-Gómez

Ann Hepatol. 2024;29:101501

5274

Full text access

Share

5258

From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.

Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner

Ann Hepatol. 2024;29:101185

5258

Full text access

Share

5258

Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells

Shuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He

Ann Hepatol. 2024;29:101279

5258

Full text access

Share

5058

Hepatitis secondary to consumption of piñalim

Leslie Moranchel–García, Eduardo Vilchis–Chaparro

Ann Hepatol. 2024;29 Supl 2:101447

5058

Full text access

Share

4981

MAFLD vs. MASLD: Consensus is unlike evidence!

Enas Kamal, Alaa M Mostafa, Yasser Fouad

Ann Hepatol. 2024;29:101527

4981

Full text access

Share